Investing in Pfizer requires patience. The company is working on replacing expiring expiring blockbuster revenue with a collection of obesity drugs, vaccines, and oncology developments.
Pfizer just released the latest updates on berobenatide, it’s GLP-1 it acquired from Metsera. Data suggested that patients lost 15% of their body fat within 14 months.
Following earlier setbacks, Pfizer restructured its metabolic focus through last year’s acquisition of Mestera for $10 billion.
Berobenatide is made to be dosed monthly, as opposed to the weekly injectables on the market—making it more attractive for users. Pfizer is looking to catchup to industry leaders Eli Lilly and Novo Nordisk, which have a strong hold of the market through first-mover advantages. Berobenatide also needs less active ingredients than competitors, allowing Pfizer the ability to streamline large-scale production.
Pfizer’s Chief Internal Medicine Officer, Jim List told Bloomberg “In Phase 2b studies, berobenatide delivered continuous, uninterrupted weight loss at all doses selected for Phase 3, while preserving a tolerable profile as people transitioned from a weekly to a monthly maintenance dose.”
List also mentioned that Pfizer’s commercial network provides an advantage as obesity care is moving towards primary-care physicians, saying “We have primary care in our DNA.”
Pfizer is utilizing its global manufacturing footprint, which has eight injectable warehouses worldwide. “We are internalizing everything because we can.”
Berobenatide is Pfizer’s ticket to the ball, the company is in a fantastic position for the obesity market and the latest news is remarkable. Competitors like Eli Lilly and Novo Nordisk are thinking of how to respond.
